Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation
Atrial FibrillationA multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients with persistent atrial fibrillation (AF).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
1. Age ≥18 years ;
2. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF
3. At least one episode of AF that is sustained beyond 3 months in duration ; documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study;
4. Modified DR-FLASH score \>=4
4. Subjects must be able to provide informed consent.
Exclusion Criteria:
1. History of previous catheter ablation for AF or left atrial flutter;
2. History of previous surgical ablation for AF;
3. Known intracardiac thrombus;
4. Contraindication to systemic oral anticoagulation therapy;
5. Reversible causes of AF;
6. Hypertrophic cardiomyopathy;
7. Severe valvular disease (mitral/aortic stenosis or regurgitation);
8. Subjects that are pregnant or breastfeeding;
9. Comorbid condition with life expectancy \< 1 year
Study Location
Southlake Regional Health Centre
Southlake Regional Health CentreNewmarket, Ontario
Canada
Contact Study Team
Atul Verma, MD
Vancouver General Hospital
Vancouver General HospitalVancouver, British Columbia
Canada
Contact Study Team
Jason Andrade, MD
Centre Hospitalier de l'Universite de Montreal (CHUM)
Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, Quebec
Canada
Contact Study Team
Jean-Marc Raymond, MD
Institute Universitaire de Cardiologie et Pneumologie du Quebec (IUCPQ)
Institute Universitaire de Cardiologie et Pneumologie du Quebec (IUCPQ)Quebec City, Quebec
Canada
Contact Study Team
Isabelle Nault, MD
Libin Cardiovascular Institute
Libin Cardiovascular InstituteCalgary, Alberta
Canada
Contact Study Team
George Veenhuyzen, MD
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contact Study Team
Allan Skanes, MD
Rouge Valley Regional Heart Centre
Rouge Valley Regional Heart CentreToronto, Ontario
Canada
Contact Study Team
Derek Yung, MD
Montreal Heart Institute
Montreal Heart InstituteMontreal, Quebec
Canada
Contact Study Team
Laurent Macle, MD
QEII Health Sciences Centre, Nova Scotia Health Authority
QEII Health Sciences Centre, Nova Scotia Health AuthorityHalifax, Nova Scotia
Canada
Contact Study Team
John Sapp, MD
University of Ottawa Heart Institute
University of Ottawa Heart InstituteOttawa, Ontario
Canada
Contact Study Team
Sacre-Coeur Hospital
Sacre-Coeur HospitalMontreal, Quebec
Canada
Contact Study Team
Mario Sturmer, MD
CIUSSS de L'Estrie-CHUS-Hopital Fleurimont
CIUSSS de L'Estrie-CHUS-Hopital FleurimontSherbrooke, Quebec
Canada
Contact Study Team
Charles Dussault, MD
Hamilton General Hospital
Hamilton General HospitalHamilton, Ontario
Canada
Contact Study Team
Jorge Wong, MD
St. Michael's Hospital
St. Michael's HospitalToronto, Ontario
Canada
Contact Study Team
Paul Angaran, MD
McGill University Health Centre
McGill University Health CentreMontreal, Quebec
Canada
Contact Study Team
Vidal Essebag, MD
- Study Sponsored By
- Ottawa Heart Institute Research Corporation
- Participants Required
- More Information
- Study ID:
NCT03347227